India's drug patent rules: Protection, override options explained

India's drug patent regime operates under a 20-year protection period from the date of filing, granting pharmaceutical companies exclusive rights to manufacture and distribute patented medications. This framework, established under the Patents Act, 1970, aims to incentivize pharmaceutical innovation while maintaining India's position as a global medicines supplier. However, the legislation includes built-in flexibility provisions that empower the government to step in when public health emergencies demand greater access to life-saving drugs at affordable prices.

The law provides two primary mechanisms through which the Indian government can circumvent patent protections. Government use allows the state to manufacture or use a patented drug without the patent holder's permission, typically for defence or public health purposes, with reasonable compensation offered to the patent owner. This provision remains largely unused, as a more frequently invoked alternative takes precedence.

Compulsory licensing represents the more common intervention tool, permitting the government to authorize third-party manufacturers to produce a patented drug without the patent holder's consent. The licensee must pay royalties to the patent owner, typically ranging from 2-6 per cent of sales. The government can invoke compulsory licensing on grounds including public health emergencies, extreme urgency, non-working of the patent, or anti-competitive practices. India granted its first compulsory licence in 2012 for the cancer drug Glivec, setting a precedent for prioritizing patient access over patent exclusivity.

These regulatory safeguards reflect India's unique position within global pharmaceutical markets. As the world's largest generic medicines producer, India supplies affordable drugs to developing nations while maintaining a domestic patent system. The flexibility built into India's patent laws acknowledges that while innovation merits protection, ensuring citizens can access essential medications at reasonable costs remains a paramount government responsibility. The framework continues to evolve through judicial interpretation and policy refinement as courts balance patent holder rights against broader public health imperatives.